Loading stock data…
Biomerica, Inc. (BMRA)
$1.77+0.02 (+1.14%)
After Hours$1.74-0.03 (-1.68%)· Last close Jun 29
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biomerica, Inc. in the Healthcare sector is trading at $1.77 with a market capitalization of $5M. The stock is currently near its 52-week low of $1.73, remaining 25.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $987,000↓ | $1.21M↓ | $1.38M↑ | $749,000↓ | $1.12M |
| Gross Profit | -$44,000↓ | $51,000↓ | $424,000↑ | -$244,000↓ | $19,000 |
| Operating Income | -$1.30M↑ | -$1.37M↓ | -$1.12M↑ | -$1.56M↓ | -$1.21M |
| Net Income | -$1.31M↑ | -$1.32M↓ | $2,000↑ | -$1.54M↓ | -$1.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnosti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-125.84%
Volume
Today's trading volume
3,186
Recent News
How Biomerica Deal Expands Henry Schein’s (HSIC) Diagnostic Ambitions and Alters Its Investment Narrative
In October 2025, Biomerica announced a marketing services arrangement with Henry Schein to promote its inFoods IBS test throughout the United States, excluding New York State, utilizing Henry Schein's network of more than 400 sales representatives targeting primary care and gastroenterology practices. This collaboration highlights Henry Schein's evolving presence in precision diagnostics, following clinical evidence for the inFoods test published in a leading gastrointestinal journal showing...
Biomerica receives approval in UAE for at-home ulcer test
The company is collaborating with local companies and healthcare providers to distribute the ulcer test.